Replay available

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call

Trevi Therapeutics, Inc. (NASDAQ: TRVI) Q2 2025 earnings conference call, held 2025-08-07. Replay captured from the company's public earnings webcast.

Thu, August 7, 2025 at 4:30 PMendedReplay
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Jennifer Good

President and CEO, Trevi Therapeutics

Lisa Delfini

Chief Financial Officer, Trevi Therapeutics

Dr. James Casella

Chief Development Officer, Trevi Therapeutics

Farrell Simon

Chief Commercial Officer, Trevi Therapeutics

Faisal Kershid

Analyst, Leerink Partners

Jason Doerr

Analyst, Oppenheimer

Annabelle Samimi

Analyst, Stifel

Alexa Deamer

Analyst, Cantor Fitzgerald

Deb Chatterjee

Analyst, Jones Trading

Serge Bellinger

Analyst, Needham & Company

Brandon Foulkes

Analyst, H.C. Wainwright & Co.

Kaveri Pullman

Analyst, Clear Street

Ryan Deshner

Analyst, Raymond James

Replay transcript excerpt

Good afternoon, and welcome to the Trevi Therapeutics second quarter 2025 earnings conference call. At this time, all participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone. To withdraw your question, please press star, then two. Please note this event is being recorded. Various remarks that management makes during this conference call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factor section of the company's most recent quarterly report on Form 10-Q, which the company filed with the SEC this afternoon. In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change. I would now like to turn the conference over to Jennifer Good, Trevi's President and CEO. Please go ahead. Good afternoon, and thank you for joining us for our second quarter 2025 earnings call and business update. Joining me today on this call are my colleagues Lisa Delfini, Trevi's Chief Financial Officer, Dr. James Casella, our Chief Developm...

More from Trevi Therapeutics, Inc.